autologous blood and marrow transplantation - Blog Science ...

More documents

Recommendations

Info

86 Chapter 2: ALL ABMT/PBSCT in CR2 4 i Single ABMT in CR1 Single PBSCT in CR1 Double-PBSCT m GMALL-Protocol 05/93 i i ii ill i i 1992 1993 1994 1995 1996 1997 1998 Figure 1. Recruitment of BCR-ABL+ patients from GMALL trials for autologous BMT or PBSCT (n=34). In vitro purging using immunomagnetic beads A total of 20 autologous bone marrow grafts were harvested from BCR-ABL + ALL patients in first (n=16) or second (n=4) morphologic CR. Purging was performed with anti-CD 19 + CD10 ±AB4 immunomagnetic beads (Dynabeads) and two separation cycles using the Baxter MaxSep device as described in detail previously. 12 ' 14 Autologous transplantation Twenty-five patients in first («=21) or second («=4) complete remission received single autologous transplants after conditioning with fractionated total body irradiation (TBI) 14.4 Gy plus 120 mg/m 2 cyclophosphamide ± 45 mg/m 2 VP-16. Of the patients autografted in CR1, seven received two courses of induction chemotherapy according to the GMALL (05/93) protocol, and 14 received three or more courses (Fig. 2). From June 1996, patients were also eligible for a pilot double autologous transplant protocol as detailed in Fig. 3. 15 RESULTS Residual BCR-ABL-positive cells in unpurged autologous grafts Before purging, residual BCR-ABL-positive cells were detected in 19 of 20 BM grafts at median 4 (range 0-6) log and in 21 of 28 évaluable PBSC grafts at median
Martin, Atta, and Hoelzer 87 Single autologous BMT in patients with BCR-ABL+ ALL (GM-ALL 05/93) > 3 cycles pretransplant Ind. I Ind. II Consolid. [ Reinduktion ] V,P,D,A E> HdAraC p-^HD-MTX x 2 Mitox. I BM-Harvest Purging CD10 + CD19 MoAbs [mmunomagnetic Beads Conditioning II fTBI14,4Gy VP-16 + CY Maintenance rIL-2/ct-IFN x4 J » L_tl Semiquantitative RT-PCR Figure 2. Treatment schedule for single autologous BMT in BCR-ABL* ALL. 1 (range 0-3) log above the limit of detection (P
Page 1:
AUTOLOGOUS BLOOD AND MARROW TRANSPL
Page 5 and 6:
AUTOLOGOUS BLOOD AND MARROW TRANSPL
Page 7:
ACKNOWLEDGMENTS We wish to thank Wi
Page 11:
THE VAN BEKKUM STEM CELL AWARD Prof
Page 14 and 15:
xii Table of Contents CHAPTER 2: AL
Page 16 and 17:
xiv Table of Contents Late Non-Rela
Page 18 and 19:
xvi Table of Contents Pretreatment
Page 20 and 21:
xviii Table of Contents CHAPTER 7:
Page 22 and 23:
XX Table of Contents Long-Term Obse
Page 24 and 25:
xxii Table of Contents CHAPTER 13:
Page 27 and 28:
0-9 LIST OF ABBREVIATIONS 2CDA 2-ch
Page 29 and 30:
List of Abbreviations xxvii EFS eve
Page 31 and 32:
List of Abbreviations MOPP mechlore
Page 33:
VOD veno-occlusive disease VPC viru
Page 37 and 38:
4HC-Purged Autologous Stem Cell Tra
Page 39 and 40:
1.0-1 + 0.2 Miller et al. 5 Event F
Page 41 and 42:
Miller et al. Adjusted probability
Page 43 and 44:
Who Benefits From Autograft in AML
Page 45 and 46:
Burnett 11 which to set the transpl
Page 47 and 48:
Table 1. Outcome after relapse in M
Page 49 and 50:
Immunotherapy in AML: No Positive E
Page 51 and 52:
Simonsson et al. inhibit IL-2 induc
Page 53 and 54:
Autologous Bone Marrow Transplantat
Page 55 and 56:
Ball et al. 21 CD15) and AML-2-23 (
Page 57 and 58:
Ball et al. 23 The ex vivo treatmen
Page 59 and 60:
Ball et al. 25 Table 2. Factors inv
Page 61 and 62:
Ball et al. Overall Survival for Pa
Page 63 and 64:
Ball et al. Overall Survival for Pa
Page 65 and 66:
Ball et al. 31 Overall Survival for
Page 67 and 68:
Ball et al. Table 4. Actuarial over
Page 69 and 70: Ball et al. myeloid leukemia. The G
Page 71 and 72: Ball et al. 1993. 38. Mehta J, Powl
Page 73 and 74: Can Autologous Stem Cell Transplant
Page 75 and 76: De Witte et al. 41 novo AML. Auer r
Page 77 and 78: De Witte et al. hematopoietic engra
Page 79 and 80: De Witte et al. 23. Fenaux P, Laï
Page 81 and 82: Stein et al. and fever. No patient
Page 83 and 84: Stein et al. after doses 1, 3, and
Page 85 and 86: Stein et al. early after the transp
Page 87: autologous stem-cell rescue. / Clin
Page 91 and 92: Bone Marrow Transplantation for Acu
Page 93 and 94: Table 2. Autologous BMT in ALL in f
Page 95 and 96: Rowe 61 or adult patients with acut
Page 97 and 98: Hoelzer and Gôkbuget minitransplan
Page 99 and 100: Hoelzer and Gdkbuget 65 blood, earl
Page 101 and 102: Table 3. Risk factors for the defin
Page 103 and 104: Hoelzer and Gôkbuget treatment opt
Page 105 and 106: Hoeker and Gökbuget tical sibling
Page 107 and 108: Sierra et al. INTRODUCTION Two-thir
Page 109 and 110: Sierra et al. Table 2. Adverse char
Page 111 and 112: 1,0 0,0 J Sierra et al. 0 20 40 60
Page 113 and 114: Sierra et al. Months Figure 4 < 30,
Page 115 and 116: Sierra et al. No adverse factors (n
Page 117 and 118: 1994. Sierra et al. 83 10. Canals C
Page 119: Martin, Atta, and Hoelzer 85 adult
Page 123 and 124: 100. Martin, Atta, and Hoelzer 89 P
Page 125 and 126: Martin, Atta, and Hoelzer 91 chromo
Page 127 and 128: Autologous vs. Unrelated Allogeneic
Page 129 and 130: Boyer and Yeager 95 outcomes after
Page 131 and 132: Boyer and Y eager 97 Table 2. Hypot
Page 133 and 134: Boyer and Y eager SUMMARY Most of t
Page 135: CHAPTER 3 CML
Page 138 and 139: Autograft Followed by Allograft Wit
Page 140 and 141: 106 Chapter 3: CML (one low-grade a
Page 142 and 143: 108 Chapter 3: CML DISCUSSION Myelo
Page 144 and 145: 110 Chapter 3: CML Philadelphia-neg
Page 146 and 147: The Case for Manipulation of CML Au
Page 148 and 149: Toward a Cure by Drug Treatment? Th
Page 150 and 151: 116 Chapter 3 :CML Table 1. Prolong
Page 152 and 153: 118 Chapter 3: CML Table 3. German
Page 154 and 155: 120 Chapter 3: CML Table 5. Normal
Page 156 and 157: 122 Chapter 3: CML Table 8. Surviva
Page 158 and 159: 124 Chapter 3: CML 88:3118-3122, 19
Page 160 and 161: 126 Chapter 3: CML RK, Klingemann H
Page 162 and 163: The Tyrphostin AG957 Inhibits the I
Page 164 and 165: 130 Chapter 3: CML mobilization. Al
Page 166 and 167: 132 Chapter 3: CML A B 100 n 0 1 5
Page 168 and 169: 134 Chapter 3: CML The in vitro sel
Page 170 and 171:
136 Chapter 3: CML detecting leukem
Page 173 and 174:
Progressive Hodglcin's Lymphoma Fol
Page 175 and 176:
Reece et al. survival is observed i
Page 177 and 178:
0.2 -I 0.0 0 Reece et al. 143 ii i
Page 179 and 180:
Reece et al. Table 3. Causes of non
Page 181 and 182:
Reece et al. carmustine, etoposide
Page 183 and 184:
CD34 + Selection of Hematopoietic B
Page 185 and 186:
Lazarus et al. 151 significantly de
Page 187 and 188:
Lazarus et al. 153 (Sigma, St Louis
Page 189 and 190:
Lazarus et al. 155 Table 2. Effect
Page 191 and 192:
Lazarus et al. 157 difference. Furt
Page 193 and 194:
Lazarus et al. 159 cells after myel
Page 195 and 196:
The European CUP/UP Trial: A Prelim
Page 197 and 198:
Table 1. Patient characteristics at
Page 199 and 200:
Schouten et al. licular non-Hodgkin
Page 201 and 202:
Sweetenham et al. vs. autologous pe
Page 203 and 204:
Table 1. Patient characteristics, g
Page 205 and 206:
Table 2. Patient characteristics, g
Page 207 and 208:
Table 3. Sites of relapse, group A
Page 209 and 210:
Table 4. Patterns of relapse, group
Page 211 and 212:
A 100 80 %OS 60 40 20 B 100 %OS | S
Page 213 and 214:
Sweetenham et al. new sites, and fi
Page 215 and 216:
Sweetenham et al. Treatment options
Page 217 and 218:
Molecular Remission: A Worthwhile A
Page 219 and 220:
Early or Late Autotransplant in Hig
Page 221 and 222:
Schenkein et al. 187 PATIENTS AND M
Page 223 and 224:
Schenkein et al. 189 Toxicity Toxic
Page 225 and 226:
Schenkein et al. 191 16. Glick JH,
Page 227 and 228:
Santini et al. 193 to evaluate the
Page 229 and 230:
Table 1. Continued Santini et al. 1
Page 231 and 232:
Santini et al. 197 cytosine arabino
Page 233 and 234:
1 0 0 1 90- 80- 70- (0 u. 60' o so-
Page 235 and 236:
Hodgkin's lymphoma. N EnglJ Med 333
Page 237:
CHAPTER 5 MYELOMA
Page 240 and 241:
206 Chapter 5: Myeloma independent
Page 242 and 243:
208 Chapter 5: Myeloma disease (MRD
Page 244 and 245:
210 Chapter 5: Myeloma Scandinavia,
Page 246 and 247:
212 Chapter 5: Myeloma (0 n o B co
Page 248 and 249:
214 Chapter 5: Myeloma B cq d ? o c
Page 250 and 251:
216 Chapter 5: Myeloma patients wit
Page 252 and 253:
218 Chapter 5: Myeloma PBSC transpl
Page 254 and 255:
220 Chapter 5: Myeloma 25. Seiden M
Page 256 and 257:
Autologous Transplantation in Multi
Page 258 and 259:
224 Chapter 5: Myeloma 0 52 44 U §
Page 260 and 261:
226 Chapter 5: Myeloma BM ^ (CD34±
Page 262 and 263:
228 Chapter 5: Myeloma IFM 94 : OS
Page 264 and 265:
230 Chapter 5: Myeloma two groups a
Page 266 and 267:
232 Chapter 5: Myeloma increase bot
Page 268 and 269:
234 Chapter 5: Myeloma REFERENCES 1
Page 270 and 271:
236 Chapter 5: Myeloma Intensified
Page 272 and 273:
238 Chapter 5: Myeloma of CD34 + ce
Page 274 and 275:
Chapter 5: Myeloma Table 2. Descrip
Page 276 and 277:
242 Chapter 5: Myeloma o 8H 0 2 4 6
Page 278 and 279:
244 Chapter 5: Myeloma ated with sh
Page 281 and 282:
The Presence of Micrometastases in
Page 283 and 284:
Kvalheim et al. 249 Table 1. Immuno
Page 285 and 286:
Kvalheim et al. 251 Figure 1. Sixty
Page 287 and 288:
Kvalheim et al. 253 DISCUSSION In t
Page 289 and 290:
Kvalheim et al. 255 Bastert G: Micr
Page 291 and 292:
Hood et al. 257 In an effort to inc
Page 293 and 294:
#CD34 + cells in blood = Hood et al
Page 295 and 296:
Hood et al. 261 Table 3. Frequency
Page 297 and 298:
Hood et al. 263 REFERENCES 1. Rill
Page 299 and 300:
The Clinical Significance of Breast
Page 301 and 302:
Moss et al. tests, and bilateral po
Page 303 and 304:
Moss et al. 269 0 15 70 143 200 400
Page 305 and 306:
Moss et al. 271 0 3 6 12 18 24 30 3
Page 307 and 308:
Moss et al. 273 8. Passos-Coelho J,
Page 309 and 310:
Autotransplantation for Men With Br
Page 311 and 312:
McCarthy et al. 277 radiation, two
Page 313 and 314:
High Dose Sequential Chemotherapy W
Page 315 and 316:
Viens et al. 281 3 g/m 2 and doxoru
Page 317 and 318:
Table 1. Tumor characteristics Exte
Page 319 and 320:
Table 4. Response Viens et al. 285
Page 321 and 322:
Viens et al. 287 Table 5. Pathologi
Page 323 and 324:
Viens et al. 289 apy for inoperable
Page 325 and 326:
Gliick et al. 291 INTRODUCTION The
Page 327 and 328:
Gluck et al. 293 RESULTS Patient de
Page 329 and 330:
Glück et al. 295 Table 3. Response
Page 331 and 332:
Gluck et al. 297 Overall Survival O
Page 333 and 334:
Gluck et al. 299 Sudbury patients w
Page 335 and 336:
Gluck et al. 301 anthracycline or t
Page 337 and 338:
Repetitive High-Dose Therapy With P
Page 339 and 340:
Prince et al. paramagnetic separati
Page 341 and 342:
Prince et al. Table 1. High-dose re
Page 343 and 344:
Table 2. Patient characteristics (n
Page 345 and 346:
Table 4. Hematopoietic recovery fol
Page 347 and 348:
1.0- M C .S 0.8- a c *fe o o> 0.6-
Page 349 and 350:
M 1.0 I 0.8H s? VI o.6H S 0.2 0.0 P
Page 351 and 352:
a Prince et al. days to platelets >
Page 353 and 354:
Table 5. Results of Isolex 300i CD3
Page 355 and 356:
Prince et al. 321 Figure 5, continu
Page 357 and 358:
Prince et al. 323 months after tran
Page 359 and 360:
Prince et al. 325 excessive to be u
Page 361 and 362:
Prince et al. 327 eight patients ha
Page 363 and 364:
Prince et al. 329 marrow transplant
Page 365 and 366:
Prince et al. intensive chemotherap
Page 367 and 368:
-Q CO .Q O 1.0 0.9 0.8 0.7 0.6 0.5
Page 369 and 370:
.Q CD .Q O 1.0 0.9 0.8 0.7 0.6 0.5
Page 371 and 372:
oba Q. 1.0 0.9 Dicke et al. Stage I
Page 373 and 374:
Vahdat with peripheral blood progen
Page 375 and 376:
Evaluation of Prognostic Factors fo
Page 377 and 378:
Fields et al. 343 PATIENTS AND METH
Page 379 and 380:
Table 1. Chemotherapy regimens. Fie
Page 381 and 382:
Fields et al. Stage II; 4-9 Pos LN
Page 383 and 384:
U U Fields et al.
Page 385 and 386:
Fields et al. 351 between 1 and 2 y
Page 387 and 388:
European Trends and the EBMT Databa
Page 389 and 390:
25% % 22% / 17% \ Rosti et al. 355
Page 391 and 392:
Rosti et al. 357 The new Italian St
Page 393 and 394:
Page 395 and 396:
Rosti et al. 6. Haas R, Schmid H, H
Page 397 and 398:
Bewick et al. 363 INTRODUCTION The
Page 399 and 400:
Bewick et al. 365 Blood samples obt
Page 401 and 402:
Bewick et al. 367 HDCT with ABSC su
Page 403 and 404:
Bewick et al. Progression Free Surv
Page 405 and 406:
Bewick et al. pression in MBC, i.e.
Page 407 and 408:
Bewick et al. 14. Kandl HL, Seymour
Page 409:
CHAPTER 7 OTHER SOLID TUMORS
Page 412 and 413:
378 Chapter 7: Solid Tumors INTRODU
Page 414 and 415:
380 Chapter 7: Solid Tumors Prepara
Page 416 and 417:
382 Chapter 7: Solid Tumors Surviva
Page 418 and 419:
384 Chapter 7: Solid Tumors months
Page 420 and 421:
386 Chapter 7: Solid Tumors have be
Page 422 and 423:
High-Dose Chemotherapy in the Manag
Page 424 and 425:
390 Chapter 7: Solid Tumors followe
Page 426 and 427:
392 Chapter 7: Solid Tumors Table 1
Page 428 and 429:
394 Chapter 7: Solid Tumors (mucosi
Page 430 and 431:
Three-Fold Intensification by Seque
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
High-Dose Therapy for Small Cell Lu
Page 438 and 439:
404 Chapter 7: Solid Tumors chemoth
Page 440 and 441:
406 Chapter 7: Solid Tumors SCLC ha
Page 442 and 443:
408 Chapter 7: Solid Tumors relapse
Page 444 and 445:
410 Chapter 7: Solid Tumors 69:585-
Page 446 and 447:
412 Chapter 7: Solid Tumors ogous b
Page 448 and 449:
414 Chapter 7: Solid Tumors 64. Bru
Page 450 and 451:
416 Chapter 7: Solid Tumors Prignot
Page 452 and 453:
418 Chapter 7: Solid Tumors CO > CO
Page 454 and 455:
420 Chapter 7: Solid Tumors TANDEM
Page 456 and 457:
Multiple Courses of Cyclophosphamid
Page 458 and 459:
424 Chapter 7: Solid Tumors and the
Page 460 and 461:
426 Chapter 7: Solid Tumors Thiotep
Page 462 and 463:
Page 464 and 465:
430 Chapter 7: Solid Tumors E 100 0
Page 466 and 467:
432 Chapter 7: Solid Tumors course
Page 468 and 469:
434 Chapter 7: Solid Tumors boplati
Page 470 and 471:
436 Chapter 7: Solid Tumors INTRODU
Page 472 and 473:
438 - Chapter 7: Solid Tumors Table
Page 474 and 475:
440 Chapter 7: Solid Tumors seeded
Page 476 and 477:
442 Chapter 7: Solid Tumors DISCUSS
Page 478 and 479:
444 Chapter 7: Solid Tumors 10. Di
Page 480 and 481:
446 Chapter 7: Solid Tumors plasma
Page 483 and 484:
Autologous Stem Cell Transplantatio
Page 485 and 486:
Keystone 451 hypertension, anemia,
Page 487 and 488:
Fassas et al. 453 INTRODUCTION Mult
Page 489 and 490:
Fassas et al. Table 2. Stem cell mo
Page 491 and 492:
Table 3. Toxicity after stem cell i
Page 493 and 494:
Fassas et al. Table 5. Trial 1: cha
Page 495 and 496:
Fassas et al. MS PROGRESSION FREE S
Page 497 and 498:
Fassas et al. ic or autologous bone
Page 499 and 500:
1 2 1 6 EAE. Burt et al. 465 Becaus
Page 501 and 502:
Burt et al. Since cyclophosphamide
Page 503 and 504:
Burt et al. 469 toxicity study, we
Page 505 and 506:
Burt et dl. All 23. Mor F, Cohen IR
Page 507 and 508:
Hasler, Gratwohl, and Tyndall an ev
Page 509 and 510:
Hasler, Gratwohl, and Tyndall 475 B
Page 511 and 512:
Kuis, Wulffraat, and Sanders 477 st
Page 513 and 514:
Kuis, Wulffraat, and Sanders neousl
Page 515:
CHAPTER 9 LONG-TERM EFFECTS
Page 518 and 519:
484 Chapter 9: Long-Term Effects po
Page 520 and 521:
486 Chapter 9: Long-Term Effects Ta
Page 522 and 523:
488 Chapter 9: Long-Term Effects ml
Page 524 and 525:
490 Chapter 9: Long-Term Effects 4.
Page 526 and 527:
492 Chapter 9: Long-Term Effects us
Page 528 and 529:
494 Chapter 9: Long-Term Effects AB
Page 530 and 531:
Page 532 and 533:
498 Chapter 9: Long-Term Effects En
Page 534 and 535:
500 Chapter 9: Long-Term Effects Rl
Page 536 and 537:
502 Chapter 9: Long-Term Effects RE
Page 538 and 539:
504 Chapter 9: Long-Term Effects A,
Page 540 and 541:
Long-Term Follow-Up of Autologous T
Page 542 and 543:
Page 545:
CHAPTER 10 GRAFT MANIPULATION
Page 548 and 549:
514 Chapter 10: Graft Manipulation
Page 550 and 551:
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
Page 584 and 585:
Page 586 and 587:
Page 588 and 589:
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596 and 597:
Page 598 and 599:
Page 600 and 601:
Page 602 and 603:
Page 604 and 605:
Page 606 and 607:
Stem Cell Reinfusion Over Two Conse
Page 608 and 609:
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
Final Report of the First Prospecti
Page 616 and 617:
Page 618 and 619:
Page 620 and 621:
Page 622 and 623:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
Page 630 and 631:
Page 632 and 633:
Page 635 and 636:
Canine Hematopoietic Stem Allograft
Page 637 and 638:
Sandmaier et al. 603 The resultant
Page 639 and 640:
Sandmaier et al. 605 synthesis path
Page 641 and 642:
Sandmaier et al. 607 interactions o
Page 643 and 644:
Sandmaier et al. 1991. 2. Burchenal
Page 645 and 646:
87:3508-3513,1996. Sandmaier et al.
Page 647 and 648:
Giralt, Khouri, and Champlin Table
Page 649 and 650:
Giralt, Khouri, and Champlin seven
Page 651 and 652:
1.0 3 0.2 Giralt, Khouri, and Champ
Page 653:
CHAPTER 12 GENE THERAPY
Page 656 and 657:
622 Chapter 12: Gene Therapy INTROD
Page 658 and 659:
624 Chapter 12: Gene Therapy RESULT
Page 660 and 661:
626 Chapter 12: Gene Therapy envisi
Page 662 and 663:
628 Chapter 12: Gene Therapy cer in
Page 664 and 665:
A Vaccine of Melanoma Peptide Loade
Page 667 and 668:
B43(anti-CD 19)-Gen i stein Immunot
Page 669 and 670:
Targeting Immunotherapy for the Tre
Page 671 and 672:
McGuinness andArceci 637 modified m
Page 673 and 674:
McGuinness andArceci 639 leukemic c
Page 675 and 676:
McGuinness and Arced 641 in G418. T
Page 677 and 678:
McGuinness andArceci 643 Figure 2
Page 679 and 680:
mRNA for hB7-1 (1491 bp) mRNA for C
Page 681 and 682:
McGuinness and Arced CD80PE C080PE
Page 683 and 684:
McGuinness andArceci 649 8. Robert
Page 685 and 686:
McGuinness andArceci immune respons
Page 687 and 688:
McGuinness andArceci 75. Jubinsky F
Page 689 and 690:
Slavin et al. 655 up suggests, as p
Page 691 and 692:
Slavin et al. 657 was a phase lib c
Page 693 and 694:
Slavin et al. presented, appears to
Page 695 and 696:
Antitumor Immunotherapy in Autologo
Page 697 and 698:
Klingemann et al. 663 Table 3. Meth
Page 699:
CHAPTER 14 RADIOIMMUNOTHERAPY
Page 702 and 703:
668 Chapter 14: Radioimmunotherapy
Page 704 and 705:
Page 706 and 707:
Page 708 and 709:
Page 710 and 711:
Page 712 and 713:
Page 714 and 715:
Selection of Radioisotopes, Chelate
Page 716 and 717:
Page 718 and 719:
Page 720 and 721:
Page 722 and 723:
Page 724 and 725:
Page 726 and 727:
Radioimmunotherapy of Common Epithe
Page 729:
CHAPTER 15 NEW AVENUES
Page 732 and 733:
698 Chapter 15: New Avenues Table 1
Page 734 and 735:
700 Chapter 15: New Avenues An alte
Page 736 and 737:
702 Chapter 15: New Avenues who can
Page 738 and 739:
704 Chapter 15: New Avenues myeloid
Page 740 and 741:
706 Chapter 15: New Avenues 48. Gir
Page 742 and 743:
Emerging Viral Infections in Blood
Page 744 and 745:
710 Chapter 15: New Avenues influen
Page 746 and 747:
712 Chapter 15: New Avenues Among a
Page 748 and 749:
714 Chapter 15: New Avenues physica
Page 750 and 751:
716 Chapter 15: New Avenues respira
Page 752 and 753:
Minimal Therapy Models of Transplan
Page 755:
CHAPTER 16 SUMMARIES
Page 758 and 759:
724 Chapter 16: Summaries although
Page 760 and 761:
726 Chapter 16: Summaries use of po
Page 762 and 763:
728 Chapter 16: Summaries Table 1.
Page 764 and 765:
Page 766 and 767:
Page 768 and 769:
Page 770 and 771:
736 Chapter 16: Summaries IL-15. Th
Page 772 and 773:
738 Chapter 16: Summaries Patterns
Page 774 and 775:
740 List of Participants Thomas L.
Page 776 and 777:
742 List of Participants Sergio A.
Page 778 and 779:
744 List of Participants Hans Marti
Page 780 and 781:
746 List of Participants David P. S
Page 782 and 783:
748 List of Participants AUTHOR IND
Page 784 and 785:
750 Author Index Hurd, D.D. 483 Kui
Page 786 and 787:
752 Author Index Stiff, Patrick J.
Page 788 and 789:
754 Key Word Index Hematologic mali
Page 792:
ISBN 1-891524-04-6
show all

autologous blood and marrow transplantation - Blog Science ...

Create successful ePaper yourself

Delete template?

Save as template?